These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 17488388

  • 21. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.
    Fernandez-Valls M, Gonzalez-Vilchez F, de Prada JA, Ruano J, Ruisanchez C, Martin-Duran R.
    Transplant Proc; 2005 Nov; 37(9):4021-3. PubMed ID: 16386615
    [Abstract] [Full Text] [Related]

  • 22. Renal function in pediatric liver transplantation: a long-term follow-up study.
    Harambat J, Ranchin B, Dubourg L, Liutkus A, Hadj-Haïssa A, Rivet C, Boillot O, Lachaux A, Cochat P.
    Transplantation; 2008 Oct 27; 86(8):1028-34. PubMed ID: 18946339
    [Abstract] [Full Text] [Related]

  • 23. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M.
    Clin Transplant; 2007 Oct 27; 21(3):305-8. PubMed ID: 17488377
    [Abstract] [Full Text] [Related]

  • 24. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
    Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, Ma MM, Mason AL, Wong WW, Bain VG, Kneteman NM.
    Transplantation; 2007 May 15; 83(9):1162-8. PubMed ID: 17496530
    [Abstract] [Full Text] [Related]

  • 25. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec 15; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
    Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL.
    Liver Transpl; 2004 Oct 15; 10(10):1301-11. PubMed ID: 15376305
    [Abstract] [Full Text] [Related]

  • 28. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation.
    Campbell MS, Kotlyar DS, Brensinger CM, Lewis JD, Shetty K, Bloom RD, Markmann JF, Olthoff KM, Shaked A, Reddy KR.
    Liver Transpl; 2005 Sep 15; 11(9):1048-55. PubMed ID: 16123966
    [Abstract] [Full Text] [Related]

  • 29. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
    Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I.
    Liver Transpl; 2008 May 15; 14(5):633-8. PubMed ID: 18324656
    [Abstract] [Full Text] [Related]

  • 30. Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors.
    Sánchez-Fructuoso AI, Ruiz JC, Calvo N, Rodrigo E, Perez-Flores I, Gómez-Alamillo C, Fernández-Pérez C, Arias M, Barrientos A.
    Transplantation; 2012 Feb 27; 93(4):398-405. PubMed ID: 22245871
    [Abstract] [Full Text] [Related]

  • 31. Indications and management of everolimus after liver transplantation.
    Bilbao I, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L, Caralt M, Blanco L, Gantxegi A, Margarit C, Charco R.
    Transplant Proc; 2009 Feb 27; 41(6):2172-6. PubMed ID: 19715864
    [Abstract] [Full Text] [Related]

  • 32. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC, Srun SW, Wood EG, Belsha CW, Marshall DL, Ferdman BR.
    J Heart Lung Transplant; 2006 May 27; 25(5):518-22. PubMed ID: 16678029
    [Abstract] [Full Text] [Related]

  • 33. Management of chronic allograft dysfunction by switch over to rapamycin.
    Sundaram V, Abraham G, Fathima N, Sundaram V, Reddy YN, Mathew M, Sathiah V.
    Saudi J Kidney Dis Transpl; 2010 Jan 27; 21(1):37-42. PubMed ID: 20061690
    [Abstract] [Full Text] [Related]

  • 34. Recovery of chronic renal impairment with sirolimus after lung transplantation.
    Venuta F, De Giacomo T, Rendina EA, Quattrucci S, Mercadante E, Cimino G, Ibrahim M, Diso D, Bachetoni A, Coloni GF.
    Ann Thorac Surg; 2004 Dec 27; 78(6):1940-3. PubMed ID: 15561004
    [Abstract] [Full Text] [Related]

  • 35. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 36. Sirolimus experience in heart transplantation.
    Aranda-Dios A, Lage E, Sobrino JM, Mogollón MV, Guisado A, Cabezón S, Hinojosa R, Hernández A, Ordóñez A.
    Transplant Proc; 2006 Oct 27; 38(8):2547-9. PubMed ID: 17097997
    [Abstract] [Full Text] [Related]

  • 37. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 27; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 38. Predictors of decline in renal function after lung transplantation.
    Barraclough K, Menahem SA, Bailey M, Thomson NM.
    J Heart Lung Transplant; 2006 Dec 27; 25(12):1431-5. PubMed ID: 17178337
    [Abstract] [Full Text] [Related]

  • 39. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 40. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
    Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, Mentha G, Giostra E.
    Liver Transpl; 2007 May 27; 13(5):658-64. PubMed ID: 17457887
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.